Qiagen N.V. (QGEN)
$
45.26
-0.19 (-0.42%)
Key metrics
Financial statements
Free cash flow per share
2.2007
Market cap
9.8 Billion
Price to sales ratio
4.7386
Debt to equity
0.5829
Current ratio
2.6001
Income quality
1.6225
Average inventory
291.4 Million
ROE
0.1148
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
QIAGEN N.V. offers comprehensive sample to insight solutions that facilitate the transformation of biological materials into valuable molecular insights globally. The company provides a range of primary sample technology consumables, including nucleic acid stabilization and purification kits tailored for primary sample materials. It supports both manual and automated processing for various applications such as genotyping, gene expression analysis, and the study of viral and bacterial samples, utilizing advanced technologies like silica membranes and magnetic beads. Additionally, QIAGEN supplies secondary sample technology consumables that include kits and components for nucleic acid purification from secondary samples. The company's product offerings extend to instruments for nucleic acid purification, various accessories, and specialized assays including interferon-gamma release assays for TB testing, post-transplant testing assays, and viral load monitoring. QIAGEN also offers prenatal testing solutions, assays for detecting sexually transmitted diseases and HPV, as well as genomic variant analysis methods that identify mutations, insertions, deletions, and fusions. The sample to insight instruments feature one-step molecular analyses designed for complex syndromes and integrated PCR testing. The company provides a multitude of PCR consumables, including quantitative PCR and reverse transcription kits furthering analysis in areas like gene expression and regulation. Moreover, QIAGEN caters to human identification and forensics with STR assays, alongside food contamination testing. Its PCR instrument line includes innovative digital PCR solutions and tailored OEM consumables. Additionally, the company provides predefined and custom NGS gene panels, library preparation kits, and services for whole genome amplification, along with various bioinformatics solutions and custom laboratory services. Recently, the company reported selling, general, and administrative expenses of $564,361,000.00 indicating its operational overhead costs. Meanwhile, it recorded a net income of $83,591,000.00 which reflects its profitability. This performance is supported by an income before tax ratio of 0.06 demonstrating a solid pre-tax margin. The earnings per share (EPS) is reported at $0.39 highlighting the company's profitability on a per-share basis. Moreover, it recorded a substantial revenue of $1,978,214,000.00 underscoring its strong market presence. The stock is affordable at $45.94 making it an attractive option for budget-conscious investors. With an average trading volume of 1,173,412.50 the stock demonstrates moderate liquidity, appealing to a range of investors. Holding a mid-range market capitalization of $9,812,624,363.00 the company positions itself as a steady performer within the competitive landscape. QIAGEN is a key player in the Medical - Diagnostics & Research industry, significantly contributing to the overall market dynamics and advancements. It belongs to the Healthcare sector, where it drives innovation and fosters growth, reinforcing its role as a leader in molecular diagnostics and related fields.
Is Qiagen N.V. (QGEN) a good investment?
Investing in Qiagen N.V. (QGEN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Qiagen N.V. (QGEN)'s stock forecast?
Analysts predict Qiagen N.V. stock to fluctuate between $37.63 (low) and $51.88 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Qiagen N.V.'s market capitalization?
As of 2025-12-12, Qiagen N.V.'s market cap is $9,812,624,363, based on 216,829,618 outstanding shares.
How does Qiagen N.V. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Qiagen N.V. has a Lower Market-Cap, indicating a difference in performance.
Does Qiagen N.V. pay dividends?
Qiagen N.V. pays dividends. The current dividend yield is 3.10%, with a payout of $0.25 per share.
How can I buy Qiagen N.V. (QGEN) stock?
To buy Qiagen N.V. (QGEN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for QGEN. Place an order (Market, Limit, etc.).
What is the best time to invest in Qiagen N.V.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Qiagen N.V. stock ever split?
Qiagen N.V.'s last stock split was 35:36 on 2025-01-29.
How did Qiagen N.V. perform in the last earnings report?
Revenue: $1,978,214,000 | EPS: $0.39 | Growth: -74.68%.
Where can I find Qiagen N.V.'s investor relations reports?
Visit https://www.qiagen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Qiagen N.V.?
You can explore historical data from here
What is the all-time high and low for Qiagen N.V. stock?
All-time high: $61.50 (2021-11-26) | All-time low: $36.84 (2023-10-30).
What are the key trends affecting Qiagen N.V. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
seekingalpha.com
Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
seekingalpha.com
Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
seekingalpha.com
Qiagen N.V. ( QGEN ) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion November 21, 2025 9:00 AM EST Company Participants Domenica Martorana - Associate Director of Global Investor Relations Thierry Bernard - CEO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Michael Scheffler Nitin Sood - Senior VP & Head of Product Portfolio & Innovation Fernando Beils Justus Krause-Harder Presentation Domenica Martorana Associate Director of Global Investor Relations Welcome to our next QIAGEN Deep Dive.
seekingalpha.com
Qiagen N.V. ( QGEN ) Jefferies London Healthcare Conference 2025 November 19, 2025 5:30 AM EST Company Participants Roland Sackers - CFO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Welcome, everybody.
proactiveinvestors.co.uk
Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) climbed 7% to 1.93p after the company unveiled a collaboration with Qiagen designed to bring its Parsortix circulating tumour cell platform to a wider range of pharmaceutical partners. The agreement gives Qiagen the ability to bundle Parsortix into projects alongside its own molecular technologies, including polymerase chain reaction, digital polymerase chain reaction and next-generation sequencing.
proactiveinvestors.co.uk
CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) has agreed a collaboration and co-marketing deal with Qiagen that will allow the diagnostics group to promote the UK company's Parsortix system to drugmakers, opening the door to new projects in circulating tumour cell research and early diagnostic development. The non-exclusive agreement enables Qiagen to offer the Parsortix platform to its pharmaceutical partners as part of projects that combine circulating tumour cell enrichment with Qiagen's polymerase chain reaction, digital polymerase chain reaction and next-generation sequencing technologies.
seekingalpha.com
Qiagen N.V. ( QGEN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 12:40 PM EST Company Participants Thierry Bernard - CEO, MD & Member of Management Board Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
seekingalpha.com
Qiagen N.V. ( QGEN ) Q3 2025 Earnings Call November 5, 2025 9:30 AM EST Company Participants John Gilardi - VP & Head of Corporate Communications Thierry Bernard - CEO, MD & Member of Management Board Roland Sackers - CFO, MD & Member of Management Board Conference Call Participants Jack Meehan - Nephron Research LLC Hugo Solvet - BNP Paribas, Research Division Douglas Schenkel - Wolfe Research, LLC Casey Woodring - JPMorgan Chase & Co, Research Division Aisyah Noor - Morgan Stanley, Research Division Patrick Donnelly - Citigroup Inc., Research Division Luke Sergott - Barclays Bank PLC, Research Division Jan Koch - Deutsche Bank AG, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.
See all news
